Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
21/08/26	US$0.000100	-75.00%	79,035
20/08/26	US$0.000400	0.00%	1,357
19/08/26	US$0.000400	+300.00%	1,015
18/08/26	US$0.000100	-75.00%	3,696
17/08/26	US$0.000400	+300.00%	3,213

Delayed Quote OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets 17:10:49 21/08/2026 BST			5-day change	1st Jan Change
0.000100 ^USD	-75.00%		0.00%	-71.43%

23/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
18/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI

Market Cap	6.17M 5.28M 4.94M 4.52M 8.49M 590M 8.6M 58.39M 22.77M 296M 23.15M 22.65M 980M	P/E 2022	-0.48x	P/E 2023	-1.34x
Enterprise Value	-71.28M -61.06M -57.13M -52.3M -98.15M -6.82B -99.45M -675M -263M -3.43B -268M -262M -11.33B	EV / Sales 2022	-4.44x	EV / Sales 2023	12.6x
Free-Float	99.93%	Yield 2022 *	-	Yield 2023	-

23/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
18/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI
28/02/25	Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares	MT
28/02/25	Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025	CI
28/02/25	Syros Pharmaceuticals, Inc. Announces Management Changes	CI
22/12/24	Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from S&P Global BMI Index	CI
13/11/24	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/11/24	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
13/11/24	Syros Pharmaceuticals, Inc. Announces Event of Default Occurred Under the Loan and Security Agreement with Oxford Finance LLC	CI
12/11/24	Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	CI
31/10/24	Syros Pharmaceuticals, Inc., Q3 2024 Earnings Call, Oct 31, 2024

13/11/24	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/11/24	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
11/05/23	JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating	MT

Syros Pharmaceuticals, Inc. Share Price

Stocks

SYRS

US87184Q2066

Biotechnology & Medical Research

Valuation: Syros Pharmaceuticals, Inc.

Chart: Syros Pharmaceuticals, Inc.

Latest news : Syros Pharmaceuticals, Inc.

Analysts' recommendations: Syros Pharmaceuticals, Inc.

Press Releases: Syros Pharmaceuticals, Inc.

News in other languages: Syros Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Syros Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

28/02/25	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration	BU
18/11/24	Syros Pharmaceuticals : Management Change/Compensation Form 8 K	PU
13/11/24	Syros Pharmaceuticals : Announces Topline Data from SELECT MDS 1 Phase 3 Trial of Tamibarotene in Higher Risk Myelodysplastic Syndrome with RARA Gene Overexpression Form 8 K	PU
12/11/24	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	BU
01/11/24	Syros Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides a Business Update	AQ

24/07/23	USA-Les valeurs à suivre à Wall Street (actualisé)
05/08/21	Bourse Zurich: le SMI termine dans le vert juste sous les 12'200 points
05/08/21	Roche signe un accord de livraison avec Syros Pharmaceuticals

1 day	-75.00%
1 month	-50.00%
3 months	-50.00%
6 months	-50.00%
Current year	-71.43%

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.02
3 years	0		8.17
5 years	0		56.4
10 years	0		243.75

Manager	Title	Age	Since
Gerald Quirk CEO	Chief Executive Officer	58	21/11/2024
Karen Hunady IRC	Investor Relations Contact	-	30/09/2022
Matthew Foster PRN	Corporate Officer/Principal	-	28/02/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/12/24	Nancy Simonian	Sell	Chief Executive Officer	37,070	0.1382%
25/11/24	Nancy Simonian	Sell	Chief Executive Officer	134,713	0.5025%
19/11/24	Gerald Quirk	Sell	Chief Financial Officer	46,657	0.1740%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYROS PHARMACEUTICALS, INC.	-75.00%	0.00%	-95.83%	-100.00%	10.73K
LONZA GROUP AG	+1.09%	+3.39%	+3.50%	+25.49%	51.22B
REVOLUTION MEDICINES, INC.	-1.07%	+3.69%	+479.26%	+607.16%	45.38B
BEONE MEDICINES AG	+1.44%	+5.19%	+21.06%	+93.98%	41.97B
IQVIA HOLDINGS INC.	+1.47%	+7.58%	+35.29%	+21.42%	42.15B
CELLTRION, INC.	-0.93%	-4.80%	+17.39%	+46.60%	31.95B
ASCENDIS PHARMA A/S	-0.60%	+2.87%	-	-	16.73B
MEDPACE HOLDINGS, INC.	+1.32%	+6.67%	+33.29%	+148.62%	17.1B
EUROFINS SCIENTIFIC SE	+0.03%	+3.91%	+5.84%	+35.04%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	+4.95%	+84.98%	+48.41%	13.91B
Average	-7.10%	+32.87%	+64.98%	+102.97%	27.52B
Weighted average by Cap.	+0.46%	+3.13%	+103.29%	+150.63%

	2022	2023
Net sales	14.88M 12.75M 11.93M 10.92M 20.49M 1.42B 20.76M 141M 54.95M 715M 55.87M 54.66M 2.37B	9.94M 8.51M 7.96M 7.29M 13.68M 951M 13.86M 94.09M 36.69M 478M 37.31M 36.5M 1.58B
Net income	-94.65M -81.08M -75.87M -69.45M -130M -9.06B -132M -896M -350M -4.55B -355M -348M -15.05B	-165M -141M -132M -121M -227M -15.75B -230M -1.56B -608M -7.91B -618M -605M -26.16B
Net Debt	-139M -119M -111M -102M -191M -13.27B -194M -1.31B -512M -6.67B -521M -510M -22.06B	-77.45M -66.34M -62.08M -56.82M -107M -7.41B -108M -733M -286M -3.72B -291M -284M -12.31B